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HISTORICAL HIGHLIGHTS
• 2014 Ebola outbreak in West Africa was the 
largest in history
• It placed unprecedented burdens upon our 
healthcare system and workers
• There is a critical need for a safe and effective 
vaccine to prevent future outbreaks of this 
devastating disease.
PREVAIL UPDATE-HISTORICAL HIGHLIGHTS
▪ The Liberian/U.S. Partnership for Research on 
Ebola Virus in Liberia (PREVAIL) was 
established in October 2014 based upon an 
exchange of letters between the then Liberian 
Minister of Health Gwenigale and U.S. Health 
and Human Services Secretary Burwell.
• A  research plan to test candidate Ebola 
Vaccines and Therapeutics was initiated.
PREVAIL UPDATE-HISTORICAL HIGHLIGHTS
* Two candidate Ebola virus vaccines had just 
entered phase 1 testing in September 2014.  
▪ Recombinant chimpanzee adenovirus Type-3 
(ChAd3)
▪ Recombinant vesicular stomatitis virus (rVSV)
▪ On February 1, 2015, the PREVAIL I Vaccine Study 
was launched at a ceremony at Redemption 
Hospital which was graced by His Excellency, 
former Vice President of the Republic of Liberia, 
Ambassador Joseph N. Boakai
PREVAIL I Study Design and consort 
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UPDATE
• Participants were followed post-vaccination at 
week 1, month 1, and every two months for 
12 months
• Overall, the vaccines were well tolerated, and 
no significant differences in reported side 
effects were found between those who 
received either of the vaccines or the placebo.
UPDATE
• Compared to placebo, both vaccines are safe 
and elicited an immune response (antibodies 
to the Ebola surface glycoprotein) by one 
month post-vaccination that was largely 
maintained through 12 months. 
• Common side effects were headaches, muscle 
pain, feverishness, and fatigue.
• No major Serious Adverse Event reported.
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+Among participants without elevated levels at entry. P-values between each active vaccine and 
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PREVAIL  I Close- out and Follow up 
Plan
• Extended to follow-up the original cohort of 
PREVAIL I study participants(1500) 
• To conduct long-term immunogenicity testing 
and collection of SAE’s for an additional 4 
years after the original 12-month visit.
• To determine the duration of the immune 
response. 
• Participants have been followed up to 
36months.
PREVAIL  I Close-out and Follow-up Plan
• All participants were invited in 
February of 2016 and educated on the 
close-out plan
• Participants randomized assignments 
were revealed individually.
• All participants were asked if they 
wanted to volunteer for follow-up 
every 12 months with blood draw at 
each follow-up visit. SAE’s events will 
be assessed at each follow-up visit.
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PARTNERSHIP FOR RESEARCH ON EBOLA 
VACcination (PREVAC)
• PREVAC means Partnership for Research on 
Ebola VACcination. It is a regional study 
ongoing in the three countries most affected 
by Ebola, Guinea, Liberia, and Sierra Leone 
plus Mali
• This is an extension of other vaccine studies 
that have been conducted in these three 
countries to investigate many unanswered 
questions about the safety and efficacy of the 
vaccines,
PARTNERSHIP FOR RESEARCH ON 
EBOLA VACcination (PREVAC)
• including the immediacy (how quickly does a 
participant elicit an immune response)
• duration of the immune response,
• and safety issues especially among children.
PREVAC in Ebola Research
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Safety and efficacy 
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PARTNERSHIP FOR RESEARCH ON 
EBOLA VACcination (PREVAC)
• Little is known about the effects of the 
vaccines on children.
• During the epidemic, children were the most 
vulnerable, with high mortality rates recorded 
among   the very young to the oldest. So, it 
was decided on that evidence to include 
children since they were the most vulnerable.
Objective
• To compare 3 vaccine strategies each with placebo  
for safety and immunogenicity in adults and 
children in three countries in West Africa where 
EVD was active during 2014 and 2015 (Guinée, 
Liberia, Sierra Leone). Mali Joined
• Vaccine strategies:  
– rVSVΔG-ZEBOV-GP vaccine without a boost 
– rVSVΔG-ZEBOV-GP vaccine, with a boost at 56 
days 
– Ad26.ZEBOV vaccine (prime vaccination) and 
MVA-BN-Filo at 56 days (boost)
Study Design Overview: a phase 2 
randomized controlled study
Blinding
• Study participants and clinical staff assessing 
the study participants for safety and 
laboratory outcomes are fully blinded until all 
participants complete 12 months of follow-up.
Data and Safety Monitoring Board 
(DSMB)
• DSMB closely monitored accumulating safety 
data for adults and children in each age group 
(1-4, 5-11, and 12-17 years). 
– Safety data for children were reviewed at least 
monthly until the DSMB was satisfied that the 
vaccines were safe and that now less frequent 
reviews are being carried out
Enrollment: age 1-17 years for the 
trial in children
Initially, only adults and children ≥12 to ≤17 years of age.
70 children aged ≥12 to ≤17 years enrolled and followed for 28 days
DSMB: consider vaccination of children ≥5 to ≤11years?
70 children aged ≥5 to ≤11 years of age
DSMB: consider vaccination of children 1 to ≤ 4 years? 
enrol 100 children between 1 and 4 years.
Safety: definition of Serious Adverse 
Events (SAE)
• Death
• Events that are life-threatening
• Events requiring hospitalisation or requiring prolongation 
of existing hospitalisation
• Events resulting in a persistent or significant incapacity
• Congenital anomaly or birth defects 
*For this protocol, EVD events and laboratory confirmed malaria 
events that do not require hospitalization will not be considered as 
SAEs.  Laboratory diagnostic criteria for confirmation of malaria should 
be based on local criteria
Safety
• Injection site reactions: redness of skin, swelling/induration, 
pain/tenderness with activity, and itching a injection site
• Targeted symptoms: reduced activity, somnolence, fatigue, 
vomiting, chills, abnormal sweating. skin lesions, mouth 
ulcers, decreased appetite, feverishness, diarrhea, nausea, 
headache, dizziness, abdominal pain, muscle pain,  joint 
swelling, and joint pain
• For non-verbal children, subjective symptoms may not be 
assessed and irritability/fussiness, crying, and screaming will 
be assessed.
PREVAC in Numbers
➢ Key dates
First participant in: 27 March 2017 (Guinea, Landreah)
3 April 2017 (Liberia, Redemption)
24 May 2017 (Guinea, Mayferinyah)
22 May 2018 (Sierra Leone, Mambolo)
12 July 2018 (Mali, CVD and UCRC)
➢ To date: 4789 participants randomized
(preliminary phases and current phase)
• 2560 Adults
• 2229 Children ( 1 to 17 years old)
PREVAC in Numbers
➢ To date: Participants randomized per country
• Guinea: 1214 Adults / 1116 Children
• Liberia: 657 Adults / 476 Children
• Sierra Leone: 397 Adults / 311 Children
• Mali: 292 Adults / 326 Children
• Funding secured through EDCTP for 4 more
years of follow-up
• PREVAC-UP will start in 2019
• 1 follow-up visit per year until 2023 = total of
5-year follow-up post vaccination
PREVAC-UP
Prevail Upcoming New Studies
• Honor Study
>  Sites: JFK/Redemption
• Malaria Study
>  Sites : Duport Rd/Rennie
• Fever Etiology  Study 
> Sites :  Redemption/?
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